KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis - Report - MDSpire
Advertisement
KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis
Clinical Report: Systematic Review and Meta-Analysis of KRAS G12C Inhibitors
Overview
This systematic review and meta-analysis evaluated the efficacy of KRAS G12C inhibitors in solid tumors, revealing improved progression-free survival (PFS) but no significant difference in overall survival (OS) compared to standard care.
Background
KRAS G12C mutations are prevalent in various solid tumors and are associated with poor prognosis due to their impact on the tumor immune microenvironment. The development of KRAS G12C inhibitors represents a significant advancement in targeted therapy.
Data Highlights
Outcome
KRAS G12Ci
Standard Care
P-Value
PFS (HR)
0.62 (95% CI, 0.53-0.74)
-
< 0.001
OS (HR)
0.93 (95% CI, 0.74-1.16)
-
0.495
ORR
3.60 (95% CI; 2.01-6.46)
-
< 0.001
PFS (PD-L1 <1%)
0.56 (95% CI: 0.38-0.83)
-
0.004
PFS (PD-L1 1%-49%)
0.58 (95% CI: 0.43-0.78)
-
< 0.001
Key Findings
KRAS G12Ci improved PFS compared to standard care (HR, 0.62).
No significant difference in OS was observed (HR, 0.93).
Objective response rate (ORR) was significantly higher for KRAS G12Ci (3.60).
PFS benefits were noted in patients with PD-L1 expression <1% and 1%-49%.
KRAS G12Ci demonstrated a better safety profile, with exceptions for diarrhea and rash.
Clinical Implications
The findings suggest that KRAS G12C inhibitors may be more suitable for patients in later-line therapy settings, particularly those with lower PD-L1 expression. Further prospective studies are needed to validate these subgroup observations.
Conclusion
KRAS G12C inhibitors show improved PFS and ORR in solid tumors, although OS remains unchanged.
